Robert W. Baird set a $22.00 price target on Karyopharm Therapeutics (NASDAQ:KPTI) in a report issued on Thursday. The firm currently has a buy rating on the stock.
Several other research analysts have also commented on KPTI. Cantor Fitzgerald set a $18.00 price target on Karyopharm Therapeutics and gave the stock a buy rating in a research report on Thursday. Canaccord Genuity lifted their price target on Karyopharm Therapeutics from $18.00 to $22.00 and gave the stock a buy rating in a research report on Monday. HC Wainwright lifted their price target on Karyopharm Therapeutics to $26.00 and gave the stock a buy rating in a research report on Thursday. BidaskClub upgraded Karyopharm Therapeutics from a buy rating to a strong-buy rating in a research report on Thursday, March 8th. Finally, Royal Bank of Canada restated a buy rating and set a $22.00 target price on shares of Karyopharm Therapeutics in a research report on Friday, March 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $19.60.
Karyopharm Therapeutics (KPTI) traded down $0.19 on Thursday, reaching $15.97. The company had a trading volume of 234,528 shares, compared to its average volume of 302,962. The stock has a market capitalization of $832.65, a price-to-earnings ratio of -6.14 and a beta of 3.62. Karyopharm Therapeutics has a 12 month low of $7.48 and a 12 month high of $18.00.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Thursday, March 15th. The company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.14). The company had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $2.26 million. Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. The company’s revenue was up 3163.8% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.65) EPS. equities research analysts expect that Karyopharm Therapeutics will post -2.66 EPS for the current year.
In other Karyopharm Therapeutics news, CEO Michael Kauffman sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $9.16, for a total transaction of $91,600.00. Following the completion of the transaction, the chief executive officer now owns 522,143 shares in the company, valued at $4,782,829.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Christopher Brett Primiano sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, March 5th. The shares were sold at an average price of $16.03, for a total value of $40,075.00. Following the transaction, the executive vice president now owns 4,881 shares of the company’s stock, valued at approximately $78,242.43. The disclosure for this sale can be found here. Insiders have sold 69,000 shares of company stock valued at $867,325 in the last 90 days. Company insiders own 14.71% of the company’s stock.
Several large investors have recently made changes to their positions in the business. MetLife Investment Advisors LLC purchased a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at approximately $146,000. Palo Alto Investors LLC raised its stake in shares of Karyopharm Therapeutics by 1.3% during the fourth quarter. Palo Alto Investors LLC now owns 3,544,439 shares of the company’s stock valued at $34,027,000 after acquiring an additional 45,854 shares in the last quarter. Millennium Management LLC raised its stake in shares of Karyopharm Therapeutics by 17.8% during the fourth quarter. Millennium Management LLC now owns 436,836 shares of the company’s stock valued at $4,194,000 after acquiring an additional 65,920 shares in the last quarter. Two Sigma Investments LP raised its stake in shares of Karyopharm Therapeutics by 76.8% during the fourth quarter. Two Sigma Investments LP now owns 24,220 shares of the company’s stock valued at $233,000 after acquiring an additional 10,520 shares in the last quarter. Finally, Deutsche Bank AG raised its stake in shares of Karyopharm Therapeutics by 16.1% during the fourth quarter. Deutsche Bank AG now owns 188,373 shares of the company’s stock valued at $1,806,000 after acquiring an additional 26,108 shares in the last quarter. Institutional investors and hedge funds own 62.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/16/karyopharm-therapeutics-kpti-given-a-22-00-price-target-at-robert-w-baird.html.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.